Iovance Biotherapeutics Q3 2026: Record Revenue and a Shrinking Loss
As seen on the 24/7 Wall St. homepage on November 5, 2026.
Cash funds operations well into 2029, taking the usual biotech dilution worry off the table for now. Amtagvi demand narrowed the quarterly operating loss to $24.0 million from $94.9 million a year ago, and management reaffirmed full-year product revenue of $410 million to $420 million.
Continue ReadingShow less
Iovance Biotherapeutics posted Q3 2026 revenue of $121.47 million, an 80.1% jump from the same quarter a year earlier and ahead of expectations. The loss per share came in at $0.05, beating expectations and underscoring how quickly the company's cost structure is shifting as Amtagvi volume grows.
The headline driver was U.S. Amtagvi revenue of approximately $102 million, with Global Proleukin contributing roughly $20 million. Gross margin climbed to approximately 60%, up from 56% the prior quarter, reflecting both the higher Amtagvi volumes and ongoing manufacturing cost optimization at the company's internal cell therapy center.
The operating loss narrowed to $24.0 million in Q3 2026 from $94.9 million in Q3 2025, a swing of more than $70 million in a single year. That improvement came without any restructuring charges, compared to $5.1 million of such charges in the year-ago period.
Sponsored
Interim CEO Frederick Vogt noted that more than 1,000 patients have now been commercially treated with Amtagvi, and the company reaffirmed full-year 2026 total product revenue guidance of $410 million to $420 million. Management also said the authorized treatment center network has surpassed 100 sites across the U.S., Canada, and Australia, with at least 110 expected by year-end.
Cash on hand is expected to fund operations well into 2029, which removes near-term dilution risk from the conversation and lets investors focus on the commercial trajectory and the pipeline, which includes an sBLA submission planned in 2027 targeting non-small cell lung cancer, a setting the company estimates is about ten times the size of the advanced melanoma market where Amtagvi is already approved.
Mentioned: IOVA